Sleeplessness, i.e., getting <7hours sleep/night (L7H), causes significant health and financial problems for individuals and industry. Sleeplessness is classified into 4 categories: difficulty initiating sleep (DIS), difficulty maintaining sleep (DMS), early morning awakening (EMA), and nonrestorative sleep (NRS). This study surveyed individuals with sleeplessness who were taking a water-soluble product of cannabinol (CBN) treated using nano technology, which has recently become available.
Individuals taking this product completed a self-evaluation survey prior to and after taking this product for at least 7days. The data was analyzed for changes in rate and severity of sleeplessness. Severity was assessed by the number of days/week for all categories except NRS, which had a symptom score with the range: -6 to +6. Significance was p < 0.001.
Sixty individuals returned the survey. For all sleep disorder categories, using this product significantly decreased incidence (L7S: 42% to 13%, DIS: 42% to 2%, DMS: 57% to 22%, EMA: 42% to 13%, NRS: 60% to 13%) and severity (L7S: 5.72+1.46 to 1.88 + 2.80, DIS: 4.77+2.12 to 0.38+1.27, DMS: 5.00+1.89 to 2.21+2.91, EMA: 4.96+1.82 to 1.7+2.76, NRS: -1.43+3.03 to 2.85+2.16). Thirteen individuals had an adverse side effect that resolved in all individuals after self-adjustment of the dose.
This nano treated CBN product rapidly induced sleep initially and after awakening, incr